HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome.

Abstract
Rituximab is a chimaeric monoclonal antibody directed against the CD20 antigen. It has been successfully used in B-cell malignancy and its efficacy in the treatment of in autoimmune hemolytic anemia and other autoimmune diseases is being investigated. There are also few case reports of its success in thrombotic thrombocytopenic purpura, but no reports of its use in hemolytic-uremic syndrome (HUS). We report a 36-year-old patient who had lost the function of her native kidneys secondary to HUS. After more than 1 year in clinical remission, she received a living unrelated kidney transplant. This immediately precipitated a severe relapse of HUS. The process was abrogated but not completely inactivated, despite over 40 plasma exchange treatments. Consequently, she was given Rituximab in courses of two to three doses, each dose 375 mg/m(2), at weekly intervals with remarkable stabilization of her disease for approximately 6 months.
AuthorsS K Yassa, G Blessios, G Marinides, R C Venuto
JournalClinical transplantation (Clin Transplant) Vol. 19 Issue 3 Pg. 423-6 (Jun 2005) ISSN: 0902-0063 [Print] Denmark
PMID15877809 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Immunosuppressive Agents
  • Rituximab
Topics
  • Adult
  • Antibodies, Monoclonal (immunology, therapeutic use)
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20 (immunology)
  • Female
  • Hemolytic-Uremic Syndrome (drug therapy, immunology)
  • Humans
  • Immunosuppressive Agents (immunology, therapeutic use)
  • Rituximab
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: